Figure S5 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

• Targeting both bcl-xl and mcl-1 led to synergistic effects in AR-V7-expressing models of CRPC.
• A-1331852, Navitoclax, and S63845 exhibited similar potency across 2D cultures and 3D spheroids, supporting their use together.
• The study utilized different models of CRPC, indicating the potential for enhanced outcomes in treatment strategies.
• Future research could explore the implications of these drugs on patient responses and therapeutic efficacy.